PDF
Capital increase in Monsenso A/S as a result of warrants exercised by employees and management
11.9.2026 13:01:38 CEST | Monsenso | Total number of voting rights and capital
Company announcement no. 09-2026
Frederiksberg, 11 September 2026
Monsenso A/S has today decided to increase the share capital by a nominal amount of DKK 84,598.80 through the exercise of warrant programs by employees and management.
The capital increase is subscribed in cash without pre-emptive rights for the company's existing shareholders or others. The proceeds amount to DKK 151,104. The capital increase represents 0.88% of the company's previous share capital.
The subscription prices for the new shares are as follows: DKK 0.11 for 357,104 new shares, DKK 0.22 for 346,676 new shares and DKK 0.25 for 142,208 new shares.
The new shares are ordinary, without special rights and freely transferable negotiable instruments. The new shares are entitled to dividends and other rights in the company from the date the capital increase is registered. The new shares will be admitted to listing on Nasdaq First North Growth Market Denmark as soon as possible after registration with the Danish Business Authority.
Monsenso's current share capital amounts to a nominal DKK 9,590,662.00 divided into 95,906,602 shares of DKK 0.10. The capital increase is expected to be completed soon, and after registration, the nominal value and volume of shares will be as follows:
Nominal value of shares DKK | 9,675,260.80 |
The volume of shares (nom. DKK 0.10) | 96,752,608 |
Any inquiries regarding this notice should be directed to:
Monsenso
CEO
Thomas Lethenborg
Tel +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
Jens Erik Thorndahl
E-mail: thorndal@monsenso.com
Certified Adviser:
HC Andersen Capital
Bredgade 23,
1260 København K.
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com